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Abstract
Female infertility, including tubal factor infertility, is a major public health concern worldwide. 
Most cases of tubal factor infertility are attributable to untreated sexually transmitted diseases that 
ascend along the reproductive tract and are capable of causing tubal inflammation, damage, and 
scarring. Evidence has consistently demonstrated the effects of Chlamydia trachomatis and 
Neisseria gonorrhoeae as pathogenic bacteria involved in reproductive tract morbidities including 
tubal factor infertility and pelvic inflammatory disease. There is limited evidence in the medical 
literature that other sexually transmitted organisms, including Mycoplasma genitalium, 
Trichomonas vaginalis, and other microorganisms within the vaginal microbiome may be 
important factors involved in the pathology of infertility. Further investigation into the vaginal 
microbiome and other potential pathogens is necessary in order to identify preventable causes of 
tubal factor infertility. Improved clinical screening and prevention of ascending infection may 
provide a solution to the persistent burden of infertility.
Overview
Infertility, which is defined as the inability to conceive after 12 months or longer of regular 
unprotected sexual intercourse, is a common public health concern worldwide. Globally, 9% 
of reproductive-aged women, including nearly 1.5 million women in the United States, are 
infertile (1, 2). The burden of infertility is inordinately higher among women in developing 
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Condensation
There is evidence that Chlamydia trachomatis and Neisseria gonorrhoeae can cause tubal factor infertility; however, additional 
pathogens also may be important factors.
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countries; in some of regions of South and Central Asia, sub-Saharan and Northern Africa, 
the Middle East, and Eastern Europe, infertility rates can reach up to 30% in reproductive-
aged women (3). The inability to conceive not only creates a considerable cost burden for 
patients and the healthcare system but is also a major psychological stressor for millions of 
couples (4). In several areas of the world, especially in low- and middle-income countries 
where having biological children is highly valued and expected of couples, involuntary 
infertility can lead to stigmatization, economic deprivation, social isolation and loss of 
status, public shame and humiliation, and in some cases, violence (5, 6). Female infertility 
may be attributed to a number of factors, typically divided into endocrine, vaginal, cervical, 
uterine, tubal, and pelvic-peritoneal factors, and although estimates vary, approximately 
15-30% of cases still remain unexplained (7). Further insight into the causes of infertility is 
necessary to help alleviate this multifactorial burden on society.
Tubal factor infertility (TFI) ranks among the most common causes of infertility, accounting 
for 30% of female infertility in the United States and is even more prevalent in certain 
communities (8). Paralleling the aforementioned global infertility disparity, TFI is 
disproportionately common in women in developing countries; for example, it has been 
shown to account for over 85% of female infertility cases in regions of sub-Saharan Africa 
compared to 33% of cases worldwide (3). Most cases of TFI are due to salpingitis, an 
inflammation of the epithelial surfaces of the fallopian tubes, and subsequent pelvic-
peritoneal adhesions, both of which are mostly caused by previous or persistent infections 
(9, 10) Bacteria ascend along mucosal surfaces from the cervix to the endometrium and 
ultimately to the fallopian tubes. This causal pathway presents itself clinically as acute 
pelvic inflammatory disease (PID), which in turn is strongly associated with subsequent TFI. 
In fact, approximately 15% of women with PID develop TFI, and the number of episodes of 
PID a woman experiences is directly proportional to her risk of infertility (11, 12). However, 
the majority of women with TFI do not have a history of clinically-diagnosed acute PID, but 
rather develop asymptomatic or minimally-symptomatic salpingitis as a result of upper 
genital tract infection (9, 13). Examining the effect of those infections, particularly those that 
occur in the absence of clinically-evident PID, is critical to understanding TFI.
Several sexually transmitted diseases (STDs), including Chlamydia trachomatis and 
Neisseria gonorrhoeae, have been widely studied to understand their role in salpingitis and 
infertility. Additionally, several other pathogens such as Mycoplasma genitalium, 
Trichomonas vaginalis, and other microorganisms within the vaginal microbiome may also 
play roles in tubal damage and other potential causes of infertility. Still, data suggest that not 
all infections yield the same long-term sequelae. The roles of different STD pathogens, co-
infections, and interactions with host characteristics, including their individual vaginal 
microbiome, may all affect a woman's subsequent ability to conceive. While screening and 
treatment efforts for C. trachomatis and N. gonorrhoeae have been developed to reduce the 
incidence of PID and subsequent TFI, additional data is needed to determine the role of 
other potential pathogens and whether early detection can prevent tubal damage. In this 
paper, we discuss the pathogens C. trachomatis, N. gonorrhoeae, M. genitalium, T. vaginalis, 
and other potential organisms that may affect female fertility, and we address the clinical 
importance of screening and preventing the spread of those infections.
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Methodology
We conducted a comprehensive literature search to identify articles by using the electronic 
databases Medline, Embase, Web of Science, and CINAHL, in addition to scrutinizing 
references of identified articles. Within each database, we combined the term “female 
infertility” with four different infection terms: “Chlamydia trachomatis,” “Neisseria 
gonorrhoeae,” “Mycoplasma genitalium,” and “Trichomonas vaginalis.” Within the Medline 
database, we refined the search by excluding the MeSH headings unrelated to female 
infertility and at least one of the four organisms. Within the Embase search, we used Emtree 
to identify terms, and used both “female infertility” and “uterine tube occlusion” as focused 
search terms to combine with each infection. We filtered results to only include articles 
published in English after 1975 until April 2016. Additional relevant articles were identified 
from bibliographies and by the recommendation of medical experts. The inclusion of the 
articles used in the analysis was based on quality of the study and relevance to this review: 
studies were excluded if they were conducted with few participants, had no comparison 
group, or constituted of case reports. Studies that did not report sufficient data to determine 
the association with female infertility or reproductive morbidities were excluded for lack of 
relevance to the topic of review.
Chlamydia trachomatis and Neisseria gonorrhoeae
C. trachomatis and N. gonorrhoeae have been extensively shown to be associated with 
infertility, particularly by causing tubal inflammation. In fact, early speculation regarding the 
effect of N. gonorrhoeae on female fertility dates back to the 1870s, when the German-born 
gynecologist Emil Noeggarath published his revolutionary claims about gonorrhea as a 
clinical condition in his book Latent Gonorrhoea in the Female Sex (14). Though he may 
have widely overestimated its repercussions (postulating that gonorrhea causes 90% of 
female infertility), his theories eventually sparked the initiation of further investigations (15). 
When the bacterium N. gonorrhoeae was finally isolated, Noeggarath's controversial claims 
regarding the persistence of this “venereal poison” in the reproductive organs and its 
pathologic consequences were reexamined (16). Studies conducted more than a century later 
have since demonstrated the impact of C. trachomatis and N. gonorrhoeae on subsequent 
infertility.
Chlamydia trachomatis, the most common reportable disease in the United States, affects 
nearly 1.5 million US citizens annually (17). Unfortunately, however, because C. 
trachomatis infections are asymptomatic in most women (18, 19), infections are often 
unnoticed, untreated, and under-reported. For almost 40 years, evidence has shown that 
untreated ascending C. trachomatis infection can lead to irrevocable damage in the fallopian 
tubes including proximal and distal tubal occlusions leading to infertility (39). The increased 
amount of heat shock protein (hsp60) synthesized by C. trachomatis induces a 
proinflammatory immune response in the human fallopian tube epithelia, resulting in 
scarring and tubal occlusion (9, 20, 21). A number of seroepidemiological studies have 
examined the prevalence of antibodies to C. trachomatis and chlamydial hsp60 in women 
with laparoscopically- or hysterosalpingographically-confirmed fallopian tube damage and 
ectopic pregnancies (22-28),, indicating that history of C. trachomatis infection is associated 
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with a significantly increased risk of tubal infertility in women, regardless of the infection 
invoking clinical symptoms (20, 25, 29-32). Extensive research has also shown that C. 
trachomatis infection can cause PID, which often precedes infertility in women. Today, C. 
trachomatis accounts for approximately 50% of cases of acute PID in developed countries 
(33). Among PID patients, those with prior C. trachomatis infection have been shown to be 
more likely to experience subsequent infertility than those without a history of C. 
trachomatis infection (32-35).
While C. trachomatis seropositivity has long been shown to influence fallopian tube patency 
(36), the use of a newer, more sensitive and specific anti-CT assay by Geisler and coworkers 
anti-CT assay has only recently been shown to hold promise as a measure of tubal function 
(37, 38). In one cohort study of 1,250 infertile women with documented tubal patency 
undergoing fertility treatment, C. trachomatis seropositivity using the antibody subclasses 
IgG1 and IgG3 was tested (39). Results showed that of these two antibody subclasses tested, 
seropositivity to C. trachomatis based on IgG3 detection was a strong predictor of both 
failure to conceive and ectopic pregnancy outcomes. Because IgG3 has been shown to be 
involved in early inflammatory response to infection (40), the detection of IgG3 in these 
women may reflect that either C. trachomatis infection has recently cleared or indicate a 
persisting infection, contributing to fallopian tube damage while perhaps not yet leading to 
blockage of the fallopian tubes (39).
In another study of subfertile women with no visible tubal pathology, chlamydial antibody 
testing was associated with a 33% lower spontaneous pregnancy rate than those without 
chlamydial antibodies (39, 41). Coppus and colleagues suggest that these low pregnancy 
rates may not only be caused by the known mechanism of chronic inflammatory response 
causing fallopian tube damage; persistent C. trachomatis infections have also been shown to 
elicit an autoimmune response to human heat shock proteins, which may elevate the risk for 
impaired embryo development and implantation (41-43). Chlamydial antibody testing may 
therefore continue to become a valuable predictor of not only tubal patency, but also of 
ectopic pregnancy, intrauterine insemination failure, and embryo and pregnancy wastage, 
independent of tubal damage.
Although less prevalent than C. trachomatis in the United States, gonorrhea is still the 
second most common reportable disease in the United States (17). N. gonorrhoeae infections 
are also often asymptomatic among women, but as Noeggarath suspected in the 1870s, the 
bacterium is capable of ascending to the upper genital tract and causing severe reproductive 
morbidities. In particular, N. gonorrhoeae attacks the epithelial cells of the fallopian tube, 
both initially by attaching to the nonciliated mucosal cells and by sloughing off ciliated 
mucosal cells (9). The resulting damage hinders the fallopian tubes’ ability to transport the 
ovum for fertilization within the tubes and implantation in the uterus, thus ultimately 
elevating the risk of infertility and ectopic pregnancy.
Several seroepidemiological studies have demonstrated the pathogen's effects on fallopian 
tube damage and subsequent infertility (44-48). Throughout those studies, women with 
laparoscopically- and hysterosalpingographically-confirmed TFI have consistently been 
shown to have a significantly higher prevalence of serologically-confirmed N. gonorrhoeae 
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infection than women with normal fallopian tubes. Like chlamydial PID, gonococcal PID 
has been shown to be an important cause of fallopian tube damage, greatly increasing a 
woman's risk of TFI. Ten to 19% of women with cervical N. gonorrhoeae infections have 
clinical signs of acute PID (50) and in regions of the U.S. with high endemic rates of 
gonorrhea during the 1970s and 1980s, gonorrhea was found in more than 40-50% of 
patients with PID (51). In recent studies, the bacteria have been identified in approximately 
20% of women diagnosed with acute PID, suggesting that N. gonorrrhoae is not as frequent 
a cause of acute PID as it had been in the past (52, 53). Still, the impact of both chlamydial 
and gonococcal infections on the fallopian tubes currently make these pathogens the most 
important known preventable causes of infertility, and improving screening programs for 
these prevalent and commonly asymptomatic pathogens may therefore make a critical 
impact in the prevention of tubal pathology and infertility.
Mycoplasma genitalium
While N. gonorrhoeae and C. trachomatis are known to be pathogens in salpingitis and tubal 
infertility, in many cases, neither organism is identified (52). Mycoplasma genitalium, a 
member of the Mollicutes class with the smallest known genome of any free-living organism 
(54), was discovered in 1981 when it was first isolated from men with non-gonococcal 
urethritis (55). After the development of nucleic acid amplification assays in the early 1990s 
facilitating its detection, M. genitalium has since been shown to be a common sexually 
transmitted organism. (56). In the United States in 2007, the prevalence of M. genitalium in 
young adults was 1%, placing it between N. gonorrhoeae (0.4%) and C. trachomatis (2.3%) 
infections, and it has been detected in 15-20% of high-risk, sexually active women in the 
United States (57-59).
Since its discovery, numerous studies demonstrate that M. genitalium is strongly associated 
with male urethritis. In an analysis of 34 studies published between 1993-2011 studying men 
with non-gonococcal urethritis, 13% of 7123 men tested positive for M. genitalium, and 
several studies have demonstrated that M. genitalium can cause persistent or recurrent 
urethritis (60). After the initial findings of M. genitalium demonstrating its effects in males, 
investigators soon began to look at its effects on the female reproductive tract. While there 
are fewer studies in women, M. genitalium has been investigated to evaluate its association 
with several morbidities in women, including cervicitis, urethritis, PID, ectopic pregnancy, 
and TFI (60).
Four serological studies have investigated the relationship between past M. genitalium 
infection in women and tubal infertility (23, 24, 61, 62). Two of those studies have 
demonstrated a significant correlation between presence of antibodies against M. genitalium 
and laparoscopically-confirmed TFI, independent of C. trachomatis seropositivity (23, 24). 
According to Svenstrup and colleagues, among women with TFI, 23% had antibodies to C. 
trachomatis and 17% to M. genitalium; whereas 15% and 4% of infertile women with 
normal fallopian tubes had antibodies to each, respectively (24). Though not quite as high as 
the prevalence of antibodies to C. trachomatis, prior M. genitalium infection is thought to be 
an independent risk factor for tubal factor infertility. In a similar study by Clausen and 
colleagues, serological analyses of women with TFI reinforced the finding that M. 
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genitalium is independently associated with tubal inflammation leading to infertility (23). A 
more recent study by Idahl and colleagues examined the association between M. genitalium 
antibodies and infertility in 239 women diagnosed with infertility of various causes, 
including laparoscopically- and hysterosalpingographically-confirmed TFI, compared to 244 
fertile controls (61). The results indicate that M. genitalium serum antibodies are more 
common among women with all causes of infertility (5.4%) than in fertile controls (1.6%). 
Among the infertile women in that sample diagnosed specifically with TFI, 9.1% were 
seropositive for M. genitalium compared with 4.6% of the fertile controls, although the 
association between TFI and M. genitalium was not statistically significant after adjusting 
for C. trachomatis seropositivity (61).
Supporting evidence has shown an association between infection with M. genitalium at the 
time of infertility evaluation and laparoscopically-confirmed tubal infertility, rather than 
serologically investigating past infection history. In a study comparing infertile and fertile 
women by polymerase chain reaction testing of cervical samples, M. genitalium was 
detected more frequently in infertile women (19.6%) compared to fertile women (4.4%) 
(63). However, in the study by Svenstrup and colleagues that examined the relationship 
between M. genitalium seropositivity and TFI, none of the women had a cervical swab 
specimen indicating current M. genitalium infection, and only one was positive for C. 
trachomatis (24). There does not appear to be a role for screening for M. genitalium 
infection at the time of infertility evaluation.
Several other studies, though not directly addressing fertility rates, have investigated the 
effects that M. genitalium may have on tubal inflammation, damage, and occlusion. The 
mechanism by which M. genitalium may cause the tubal scarring that leads to infertility has 
been studied through several in vitro models. McGowin and colleagues demonstrated that 
the organism can attach to reproductive tract epithelial cells and elicits cellular immune 
responses that result in inflammation (65, 66). In another in vitro organ culture model, M. 
genitalium adhered to human fallopian tube epithelium after experimental inoculation, 
causing swelling of the cilia and detachment of cilia from the epithelium (67). Svenstrup and 
colleagues also investigated whether mobile sperm could serve as a vector for transmitting 
M. genitalium to the upper genital tract of women, demonstrating that the organism does 
adhere to human spermatozoa and could be transported by sperm to the uterus and fallopian 
tubes to colonize and destroy the ciliated epithelia (68).
When compared with the more severe damage that C. trachomatis and N. gonorrhoeae 
infection create in the fallopian tube, the damage caused by M. genitalium tends to be 
moderate (65). However, when left untreated, damage may accumulate and yield serious 
long-term sequelae on fallopian tube function. Additionally, simultaneous infection with M. 
genitalium and other sexually transmitted bacteria may cause even more severe tubal 
pathology. One study conducted in Saudi Arabia used PCR performed on tubal samples 
from women with ectopic pregnancy and compared them to samples from fertile women 
undergoing partial sapingectomy for sterilization or at the time of hysterectomy (69). They 
found a 6-fold higher rate of infection with C. trachomatis and M. genitalium in women with 
ectopic pregnancy compared to the controls. There was also a higher rate of other infections, 
including U. urealyticum/parvum, G. vaginalis, N. gonorrhoeae, and T. vaginalis, but these 
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associations were not statistically significant. The investigators noted that co-infection with 
at least 2 organisms led to a 5-fold increase in the risk of ectopic pregnancy, providing 
further evidence that multiple infections leads to greater risk of tubal damage (69).
Animal studies have also been performed to investigate the potential role of M. genitalium 
on tubal scarring and inflammation. Female grivet monkeys and marmosets inoculated with 
M. genitalium developed severe endosalpingitis, along with luminal exudates and adhesions 
between mucosal folds in the fallopian tubes, similar to changes induced by chlamydial 
infection (70). Additionally, female Swiss Webster mice developed upper reproductive tract 
infection as early as 3 days after being inoculated with M. genitalium, showing 
experimentally that M. genitalium is capable not only of ascending through the upper genital 
tract, but persistently colonizing reproductive tract tissues that could lead to long-term tubal 
inflammation and occlusion (71).
Both serological and epidemiological studies have explored whether M. genitalium is 
associated with clinical PID and salpingitis. In an analysis of 193 patients with clinically-
diagnosed PID and 246 healthy pregnant controls, 17% were M. genitalium seropositive, 
although the association was not statistically significant after adjusting for age and presence 
of antibodies to C. trachomatis (72). An older study by Møller and colleagues also showed 
an association; in a group of patients with acute PID without C. trachomatis antibodies, 
almost 40% had a four-fold or greater change in the titre of Mycoplasma genitalium 
antibodies (73). Still, results are conflicting, as Lind and colleagues assessed the significance 
of antibodies to M. genitalium in patients with acute salpingitis and failed to confirm any 
association (74).
Recent studies have examined the relationship between current cervical or endometrial M. 
genitalium infection and upper genital tract infection (74-78). In an analysis of 586 women 
who participated in the PID Evaluation and Clinical Health (PEACH) Study, a randomized 
multicenter clinical trial in the United States, 31% of women who tested positive for M. 
genitalium in the endometrium reported recurrent PID, 42% had chronic pelvic pain, and 
22% were infertile (75). However, a large prospective trial of 2378 young women in London 
failed to show an association between M. genitalium and acute PID. Among women with M. 
genitalium at baseline, 3.9% developed PID after 12 months compared with 1.7% of women 
without baseline infection; however, this difference was not statistically significant (66). 
Oakeshott and colleagues concluded that because the population attributable risk of PID due 
to M. genitalium was only 4%, M. genitalium infection is not an important risk factor for 
pelvic inflammation (79). This particular European population may not be generalizable to 
populations with higher prevalence rates of M. genitalium infection, where, if confirmed, 
this two-fold increased risk of PID due to M. genitalium infection could constitute a major 
public health problem (75). Still, while evidence shows that M. genitalium is often present in 
or associated with PID cases, more data is necessary to determine the role of this 
microorganism in the pathogenesis of PID and subsequent TFI.
M. genitalium may not only affect tubal patency; several studies have investigated its effects 
on pregnancy outcomes such as ectopic pregnancy, recurrent pregnancy loss, and preterm 
birth. However, unlike for C. trachomatis, there is limited evidence that the pathogen is 
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associated with these adverse pregnancy outcomes. A serological case-control study by 
Jurstrand and coworkers showed no significant correlation between M. genitalium antibodies 
and ectopic pregnancy (80). According to a recent meta-analysis, M. genitalium infection 
has been shown to be significantly associated with increased risk of both spontaneous 
abortion and preterm birth in some studies, although evidence is inconsistent (81). While 
data is emerging on the impact of M. genitalium on the reproductive health of women, 
further research is necessary to solidify any conclusions regarding M. genitalium and 
adverse pregnancy outcomes.
Trichomonas vaginalis
Like that of M. genitalium, the role of Trichomonas vaginalis infection in reproductive tract 
pathology has been understudied, but investigators have shown that it may be associated 
with female infertility. T. vaginalis is the most common non-viral, sexually transmitted 
pathogen in the United States. According to the World Health Organization, the protozoan T. 
vaginalis accounts for more than half of all curable STDs worldwide (82). An estimated 7.4 
million new infections occur annually in the U.S. (83) and approximately 3.1% of 
reproductive-age women are infected (84). Given the high prevalence of T. vaginalis in the 
population, any potential impact of the organism on the upper reproductive tract could 
constitute a serious public health concern.
Data associating T. vaginalis with TFI and pelvic inflammation in the literature is relatively 
weak. Few retrospective studies have found that women with self-reported infertility were 
2-3 times more likely to have a current T. vaginalis infection, and women with a self-
reported history of a T. vaginalis infection have approximately a two-fold risk of tubal 
infertility (45, 84-88). Additionally, a trend exists between increasing number of episodes of 
T. vaginalis infection and increasing risk of infertility (45). However, many of the 
epidemiologic studies analyzing the association between trichomoniasis and infertility failed 
to control for important confounding variables such as presence or history of other 
reproductive tract infections.
Upon investigation of endometrial inflammatory changes elicited by infections, 
immunohistochemical evidence shows that T. vaginalis may contribute to upper genital tract 
inflammation (89). Pathologically, T. vaginalis has been shown to be capable of ascending 
the upper genital tract and has been associated with up to 30% of acute salpingitis cases, 
although within the same study, trichomonads were not demonstrated in tubal cultures from 
cases of salpingitis (90). T. vaginalis has been shown to be associated clinically with 
endometritis, salpingitis, and atypical PID (91-94), demonstrating that it may be an 
important pathogen in upper genital tract damage. Other potential mechanisms linking T. 
vaginalis infection to infertility include disruption of sperm motility (93), phagocytosis of 
sperm, and transportation of other infectious agents to the upper genital tract by motile 
trichomonads (86, 87), although these mechanisms do not directly affect the female 
reproductive tract.
Co-infection of T. vaginalis and C. trachomatis may increase the risk of upper genital tract 
infection more than the risk of C. trachomatis infection alone, and women with both T. 
vaginalis and HIV-1 have been shown to have a significantly higher risk of PID than women 
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without T. vaginalis (87, 94). Because trichomonads are capable of phagocytizing bacteria, 
yeast, vaginal epithelial cells, mycoplasmas, and herpesviruses in vitro (96-99), investigators 
speculate that T. vaginalis infection may be capable of spreading other pathogens throughout 
the upper genital tract, thereby indirectly eliciting tubal damage and infertility. Moreover, 
despite some of these weak associations, proposed mechanisms, and possible co-infection 
risks, there is currently no strong conclusive evidence regarding the causative effects of T. 
vaginalis on PID or infertility.
Vaginal Microbiome and Other Potential Pathogens
N. gonorrhoeae, C. trachomatis, and M. genitalium may not be the only organisms capable 
of damaging the reproductive tract. Both Mycoplasma hominis and Ureaplasma urealyticum, 
two common species of genital mycoplasma, have been investigated as possible causative 
agents for infertility and pelvic inflammation. M. hominis is commonly found in the upper 
genital tract. The adverse influence of M. hominis on the female reproductive tract was 
identified in 1976 by Mårdh and colleagues, as they demonstrated with in vitro organ 
cultures the swelling of the ciliated tubal epithelial cells due to M. hominis infection (100). 
The organism has been isolated from the fallopian tubes of women with a history of 
infertility and laparoscopically-confirmed salpingitis, although recent data have not 
necessarily reproduced these findings (62, 90, 101, 102).
Ureaplasmas, including U. urealyticum, have also been investigated as potential culprits of 
female infertility. Like M. hominis, ureaplasmas have been isolated from the fallopian tubes 
of patients with PID, yet their presence in patients with PID is rare (90, 103). Some studies 
suggest a causal relationship between U. urealyticum and infertility, but most controlled 
studies do not confirm such a pathogenic role. Evidence supporting both M. hominis and U. 
urealyticum as agents involved in infertility is not nearly as conclusive as existing evidence 
for pathogens such as C. trachomatis and N. gonorrhoeae; while some investigators have 
been able to detect each of the organisms in infertile patients and in patients with upper 
genital tract disorders, several have not shown any correlation (103-106). As with T. 
vaginalis, the existing evidence for M. hominis and ureaplasmas as pathogens causing 
infertility is therefore not sufficiently definitive.
While the focus of this review was to identify sexually transmitted pathogens that affect 
fertility, other infectious diseases are important to consider in discussing infertility. In the 
developing world where exposure to Mycobacertium tuberculosis is common, genital 
tuberculosis (GTB) is a significant cause of infertility. Though its incidence is less than 1% 
in industrialized countries, GTB rates can be as high as 13% in developing countries, 
eliciting a major public health concern (107). In almost all cases of GTB, Mycobacertium 
tuberculosis spreads hematogenously from a primary source, most commonly the lungs, to 
the fallopian tubes, producing irreversible tubal damage and ultimately leading to TFI in up 
to 40% of cases (1). In addition to infertility, GTB has also been shown to be an important 
risk factor for ectopic pregnancy in developing countries (108, 109). The silent nature of 
GTB, which often persists without any clinical manifestations, allows development of 
fulminating infection without detection (110). Early detection and treatment of GTB is vital 
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to improve reproductive outcomes, but unfortunately provides no benefit to reverse tubal 
damage once the disease is advanced (111).
Rather than a single organism impairing female fertility, variations in the overall vaginal 
microbiome, such as in bacterial vaginosis, may also have a role in infertility (112). A recent 
meta-analysis exploring the role of bacterial vaginosis (BV) on infertility has shown that BV 
is significantly more prevalent in infertile women than in pregnant women of the same 
population (113). According to this systematic review of 12 studies reporting the prevalence 
of BV in patients with infertility of all subtypes, an estimated one in five infertile women has 
BV, and at least one in three has an abnormal vaginal microflora. Four studies have shown 
that BV is significantly more prevalent in women with tubal infertility than in women with 
non-tubal infertility (114-117), including a recent study among Nigerian women that 
demonstrated that BV was four times more prevalent in women with TFI compared to fertile 
controls (117). Additionally, after adjusting for several factors, including current infection 
with N. gonorrhoeae, C. trachomatis, or T. vaginalis, BV has been linked to 
laparoscopically-confirmed PID, endometritis, and salpingitis (114, 118-121), suggesting 
that the effects of BV are not confined to the lower genital tract and may therefore interfere 
with female fertility. In fact, microorganisms that are highly prevalent in the vagina among 
women with BV have been recovered in the fallopian tubes of women with laparoscopically-
confirmed PID and acute salpingitis (122).
However, the role of BV in infertility and in upper genital tract morbidity is still not 
completely clear, as other studies refute any significant correlation (123). Likewise, the 
studies that do show correlations between BV and tubal pathology do not necessarily help 
distinguish whether this finding is secondary to previous tubal damage caused by infections 
such as C. trachomatis and N. gonorrhoeae, or whether BV infection may help spread these 
infections to the upper genital tract (116). It is uncertain whether or not BV itself is the 
direct cause of damage on the fallopian tubes, but given its high prevalence among women 
with TFI, alongside the high percentage of women with BV that remain undiagnosed and 
untreated, further investigations elucidating the role of anaerobic overgrowth, biofilms, and 
the vaginal microbiome are needed (117).
Conclusions
In summary, the totality of the evidence linking N. gonorrhoeae and C. trachomatis to 
infertility is compelling. However, the associations found between M. genitalium, T. 
vaginalis and other potential pathogens are suggestive, but far from definitive. Additional 
research is necessary to strengthen the suggestions that M. genitalium and T. vaginalis can 
cause infertility. We would recommend additional serological studies in a diverse sample of 
reproductive age women while controlling for the history of other STDs. Prospective studies 
assessing demographic and behavioral factors, the impacts of co-infections, and the impact 
of the vaginal microbiome are needed to sort out the relationship between these pathogens 
and impaired fertility and adverse pregnancy outcomes.
Nonetheless, for those pathogens where reproductive tract pathology is evident, screening 
and treatment should be emphasized in the clinical setting. The literature regarding the 
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importance and benefit of treating these pathogens to enhance fertility on the population 
level is sparse, although a recent study in Washington observed a potential association 
between disease management trends and reduction of reproductive morbidities (53). While 
further investigations are necessary to establish a tangible benefit, it is nonetheless well-
understood that women who delay seeking care for what is often an asymptomatic infection 
have a higher risk for infertility and other reproductive morbidities. The U. S. Preventive 
Services Task Force has issued chlamydia and gonorrhea screening recommendations since 
2000 to reduce associated morbidities (124), but such guidelines regarding other non-
traditional pathogens have not been established. Future research to evaluate the impact of 
screening and treatment programs for non-traditional pathogens such as Mycoplasma 
genitalium and other organisms in the microbiome should be considered to help guide 
clinical practice and health policy to more effectively reduce the global burden of infertility.
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